DMU2105 is a potent CYP1B1 inhibitor with IC50 value of 10nM for human CYP1B1 enzyme bound to yeast-derived microsomes (Sacchrosomes™).

Gemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.

Acumapimod is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α.

SR-3677 is a potent and selective ROCK-II inhibitor with an IC50 of ~3 nM in enzyme and cell based assays, and its IC50 for ROCK-I is 56 ± 12 nM.

Urolithin A is a metabolite of ellagitannin with antiproliferative and antioxidant properties. It can cross the blood brain barrier, and may have neuroprotective effects against Alzheimer’s Disease. Urolithin A has been shown to stimulate mitophagy and improve muscle function in aged animals15 and in models of muscular dystrophy,16 while also being safe, bioavailable, and able to induce mitochondrial gene expression in older adults.

CA-5f is identified as a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. It exhibted potential clinical application for NSCLC therapy.

AC55649 is an agonist of the retinoic acid receptor β (RAR-β).

TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM.

20-Deoxyingenol is a natural compound.

SD-06 is a p38 MAP kinase inhibitor and inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats(83% inhibition at 1mg/kg, po).

AZD7624 is an inhaled p38 inhibitor, with potent anti-inflammatory activity.

(E)-3PO is a small-molecule inhibitor of the PFKFB3 isozyme, 3PO markedly attenuates the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50, 1.4-24 μM) which target: PFKFB3 isozyme. 3PO inhibits recombinant PFKFB3 activity, suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH in vitro.